Bold Therapeutics is a clinical-stage biopharma company based in Vancouver, British Columbia founded in 2018 to develop and commercialize BOLD-100, a first-in-class small molecule therapeutic with applications in both oncology and infectious disease (COVID-19).

Based on compelling preclinical and early clinical results, Bold Therapeutics is focusing its clinical development efforts on some of the most challenging indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.

Our Team

Profile Photo

E. Russell McAllister
Chief Executive Officer

  • More than 20 years of biopharma industry experience, focusing on corporate strategy, finance, and business development
  • 2018 CFO of the Year Honoree, Tampa Bay Business Journal (TBBJ)
  • 2017 ‘Deal of the Year’ recipient; Southeast Bio (SEBIO)
  • Former Managing Director, Head of Healthcare Strategic Advisory
  • 5-Star-Rated Senior Equity Research Analyst (Biopharmaceuticals)
  • PhD candidate, Behavioral Finance, University of Illinois; MS Accounting / MBA, Northeastern University
Profile Photo

Jim Pankovich
Executive Vice President, Clinical Development

  • More than 25 years of biopharma industry experience, focusing on clinical study strategy and management.
  • VP, Clinical Operations and Drug Development, Qu Biologics (Immuno-oncology). Former CSO, CIHR Canadian HIV Trial Network (Infectious disease); Sr Director, Clinical Research, Migenix (Infectious disease); Assc Director, Clinical Research, Inex Pharmaceuticals (Oncology)
  • MS, Experimental Medicine, University of Alberta
  • MBA, Queen’s University
Profile Photo

Michelle Jones
Director, Clinical Development

  • More than 20 years of biopharma industry experience, focusing on clinical trial management and operations.
  • Associate Director, Clinical Operations, Qu Biologics (Immuno-oncology). Clinical Operations Manager, Symvivo (Immuno-oncology); Former Research Manager, CIHR Canadian HIV Trial Network (Infectious disease); Clinical & Regulatory Affairs Manager, Protiva Biotherapeutics (Oncology & Infectious disease)
  • MSc, Nursing, McGill University
  • MBA (Management of Biotechnology Specialization), Simon Fraser University
Profile Photo

Mark Bazett, PhD
Director, Preclinical Development

  • 5 years of biopharma industry experience, focusing on preclinical development.
  • Former Preclinical Immunotherapy Lead, Novelogics (Oncology); Director of Preclinical and Translational Research, Qu Biologics (Immuno-oncology)
  • PhD, Immunology, McGill University
Profile Photo

Adam Carie, PhD
Director of CMC & Nonclinical Development

  • More than 10 years biopharma industry experience developing novel oncology therapeutics, including IVECT™ polymer nanoparticle technology from concept to clinic.
  • More than 10 years of biopharma industry experience, focusing on oncology product development, formulation, optimization, logistics and manufacturing.
  • Focus on nonclinical development, manufacturing, quality systems, supply chain management, logistics, and regulatory support.
  • Current Director of Product Development for Intezyne, also managed CMC for BOLD-100 during development at Intezyne.
  • PhD in Cancer Biology from University of South Florida. PhD research in Cancer Drug Discovery at H. Lee Moffitt Cancer Center in Tampa, FL.
Profile Photo
Matthew Sebastiani
Corporate Development Associate
  • MBA (Finance) UBC Sauder School of Business; BA (Hons) Economics, Simon Fraser University
  • Former VP Finance and Operations, Novelogics (Oncology)
  • Several years of experience in government and financial services, including as a policy advisor for the Senate of Canada.
  • Responsible for supporting corporate development, finance, accounting, and investor relations.
Profile Photo
Paromita Raha, PhD
Senior Scientist, Preclinical Research
  • 6 years of experience in Preclinical and Clinical Research in Oncology.
  • 4 years of industry experience in pharmaceutical and food technology sectors.
  • Former Senior Scientist, Lecker Labs (Food technology), Research Scientist, SignalChem (Oncology).
  • Postdoctoral Scholar, Translational Oncology, UCSF.
  • Ph.D., Structural Biology, University of Calcutta.
Profile Photo
Malcolm Snow
Preclinical and Clinical Researcher
  • BSc, Psychology (Co-op), Memorial University of Newfoundland.
  • Research experience concentrated on medical weight loss surgeries and medication interactions.
  • Finance Coordinator for Obesity Canada’s Student and New Professionals (OC-SNP) student executive.
  • Responsible for supporting preclinical and clinical research initiatives, as well as providing support for business development.
Profile Photo
Melissa Smith
Office Manager
  • BA, Criminology (Concentrations: Psychology and Sociology), University of the Fraser Valley
  • AA, Kinesiology (Concentrations: Anatomy and Physiology), Langara College
  • Responsible for office management, conference and travel logistics, and providing support for accounting, business development, finance and investor relations.
Profile Photo
Carly Hastings
Operations Associate
  • BS, Health Sciences (Concentrations: Health Management and Biological Sciences), University of South Florida
  • Responsible for accounting, clinical trial logistics and procurement, as well as providing support for business development, finance and investor relations.
Profile Photo
Elizabeth Daley
Executive Assistant
  • BS, Cell and Molecular Biology, University of South Florida.
  • BS, Health Sciences (Concentration: Health Management), University of South Florida.
  • Responsible for competitive intelligence and providing support for accounting, business development, and investor relations.
Board Of Directors

Board Of Directors

Glenn Walthall
E. Russell McAllister
Jim Pankovich
EVP Clinical Development
Simon Sutcliffe
Hooshmand Sheshbaradaran


Although Bold is not currently hiring for specific positions, we encourage exceptional candidates to contact us at [email protected]